NICE not recommending Eisai's lenvatinib for additional thyroid indications

The U.K.'s NICE issued draft guidance recommending against the use of Lenvima lenvatinib to treat advanced differentiated thyroid cancer that has spread to other parts of the body and cannot be operated on.

The agency said Eisai Co. Ltd. (Tokyo:4523) has agreed to a confidential patient access scheme to provide the drug at a discount, given that the most plausible incremental cost effectiveness ratio (ICER) for lenvatinib was "considerably higher" than the £30,000 ($39,432) per quality-adjusted life year gained...